In mice bearing a flank LLC tumor (~80 mm3 on day 1), we tested the efficacy of BEMPEG (16 μg, IV on days 6, 15, 24) and anti-CTLA-4 treatments (200 μg, IP on days 4, 7, 10) combined with local treatment of the tumor through surgical resection (day 16) or delivering three fractions of 8 Gy RT (days 1, 2, 3). This evidence concerns the gene CTLA4 and neoplasm.